Teva Pharmaceutical Industries Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard Francis
- Full Time Employees
- 33,346
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- 124 Dvora Hanevi’a Street Tel Aviv TA Israel 6944020
- IPO Date
- Jan 1, 1951
- Website
- tevapharm.com
- Similar Companies
- Business
- Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited develops, manufactures, markets and distributes generic medicines, innovative and specialty biopharmaceutical products worldwide. The company offers a broad portfolio of generic medicines in various dosage forms including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams; sterile products, hormones, high-potency drugs and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. Its key branded products comprise Austedo (deutetrabenazine) for chorea associated with Huntington's disease and tardive dyskinesia; Ajovy (fremanezumab) for preventive migraine treatment in adults; Copaxone for relapsing forms of multiple sclerosis; and Bendeka and Treanda injections for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, alongside active pharmaceutical ingredients and over-the-counter offerings. Teva operates in the United States, Europe, Israel and internationally, with manufacturing facilities across North America, Europe, Australia, South America and Israel; it maintains headquarters in Petah Tikva, Israel, tracing origins to predecessors founded in 1901 and incorporating as Teva in 1935. Recent developments include increased 2025 revenue outlook for Austedo and non-GAAP EPS following third-quarter 2025 results showing $4.5 billion in revenues up 3% year-over-year; a strategic partnership announced in February 2024 with Jiangsu Nhwa Hexin for Austedo marketing and distribution in China; and presentation of positive Phase 2b study results for duvakitug (anti-TL1A) in collaboration with Sanofi at ECCO 2025, alongside heightened R&D investments in immunology, immuno-oncology and neuroscience pipelines.
Company News
Teva to Host R&D Day on Wednesday, November 11 in New York City
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
Teva's Branded Drugs Take Center Stage in Its Growth Strategy
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
QRG Capital Management Inc. Purchases 12,925 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
Teva Releases Q3 2026 Aide Memoire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript